{"id":51450,"date":"2022-12-01T14:02:03","date_gmt":"2022-12-01T13:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/"},"modified":"2022-12-01T14:02:03","modified_gmt":"2022-12-01T13:02:03","slug":"august-bioservices-closes-65m-series-b","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/","title":{"rendered":"August Bioservices Closes $65M Series B"},"content":{"rendered":"
\n

\nFunding enables August Bio to add capacity for large batch sterile pharmaceutical manufacturing<\/i>\n<\/p>\n

NASHVILLE–(BUSINESS WIRE)–August Bioservices, LLC (\u201cAugust Bio\u201d), a pharmaceutical contract development and manufacturing organization (CDMO) providing drug discovery, development and pharmaceutical manufacturing services, today announced that it secured $65 million in Series B funding led by Oak HC\/FT, who led the Series A in July 2020. This round includes participation from existing investor, Polaris Partners.\n<\/p>\n

<\/a><\/p>\n

\nThe new funding will be used to expand August Bio\u2019s capacity to meet the growing development and manufacturing needs of its current customers and new customers. The company will add an additional sterile injectable filling suite to support high-speed liquid vial filling. This expansion will add incremental capacity for production of large batches, enabling August Bio to meet the pharmaceutical manufacturing needs for customers of all sizes. In addition, the company will fully automate downstream inspection, labeling and packaging processes in support of the increased throughput.\n<\/p>\n

\n\u201cThis round is a testament to our support of August Bio\u2019s plans to deliver greater impact through the expansion of high-quality aseptic fill\/finish capacity,\u201d said Andrew Adams of Oak HC\/FT. \u201cAs demand increases for U.S.-based sterile injectable manufacturing, investment in companies like August Bio, with a rigorous commitment to quality, is essential.\u201d\n<\/p>\n

\n\u201cThis funding will enable August Bio to serve larger scale biopharmaceutical customers from our Nashville facility and to more significantly meet our customers\u2019 growing demand for sterile manufacturing. Ultimately, we will be better resourced to deliver critical medications to patients who need them,\u201d said Jenn Adams, CEO of August Bio. \u201cWe are excited about the opportunity to scale our manufacturing capacity and we appreciate the continued support from our investors.\u201d\n<\/p>\n

\nAbout August Bioservices<\/b>\n<\/p>\n

\nHeadquartered in Nashville, TN, August Bioservices, LLC is a high-tech, growth-focused, and innovative provider of Contract Research, Development and Manufacturing services, that plays a crucial role in the global pharmaceutical industry supply chain. August Bioservices partners with biopharmaceutical and biotech companies to provide a wide array of services that help to accelerate the advancement of novel therapeutics along the drug development pathway.\n<\/p>\n

\nFor more information about August Bio\u2019s full line of services: www.augustbio.com<\/a>.\n<\/p>\n

\nAbout Oak HC\/<\/i>FT<\/b>\n<\/p>\n

\nOak HC\/FT is a venture and growth equity firm investing in companies driving transformation in healthcare and fintech, two uniquely complementary and high-growth sectors. With deep domain expertise and strategic resources, Oak HC\/<\/i>FT partners with leading entrepreneurs at every stage, from seed to growth, to build businesses that make a measurable, lasting impact on these industries. Founded in 2014, the firm has $5.3 billion in assets under management and is headquartered in Stamford, CT, with investors in San Francisco and Boston. Follow Oak HC\/<\/i>FT on Twitter and LinkedIn and learn more: www.oakhcft.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCary Martin
\n
Vice President, Marketing
\n
615-515-5404
\n
cmartin@augustbio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Funding enables August Bio to add capacity for large batch sterile pharmaceutical manufacturing NASHVILLE–(BUSINESS WIRE)–August Bioservices, LLC (\u201cAugust Bio\u201d), a pharmaceutical contract development and manufacturing organization (CDMO) providing drug discovery, development and pharmaceutical manufacturing services, today announced that it secured $65 million in Series B funding led by Oak HC\/FT, who led the Series A … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51450","6":"format-standard","7":"category-industry"},"yoast_head":"\nAugust Bioservices Closes $65M Series B - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"August Bioservices Closes $65M Series B - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Funding enables August Bio to add capacity for large batch sterile pharmaceutical manufacturing NASHVILLE–(BUSINESS WIRE)–August Bioservices, LLC (\u201cAugust Bio\u201d), a pharmaceutical contract development and manufacturing organization (CDMO) providing drug discovery, development and pharmaceutical manufacturing services, today announced that it secured $65 million in Series B funding led by Oak HC\/FT, who led the Series A ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-01T13:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221201005209\/en\/1651798\/21\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"August Bioservices Closes $65M Series B\",\"datePublished\":\"2022-12-01T13:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/\"},\"wordCount\":477,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005209\\\/en\\\/1651798\\\/21\\\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/\",\"name\":\"August Bioservices Closes $65M Series B - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005209\\\/en\\\/1651798\\\/21\\\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg\",\"datePublished\":\"2022-12-01T13:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005209\\\/en\\\/1651798\\\/21\\\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005209\\\/en\\\/1651798\\\/21\\\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/august-bioservices-closes-65m-series-b\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"August Bioservices Closes $65M Series B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"August Bioservices Closes $65M Series B - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/","og_locale":"en_US","og_type":"article","og_title":"August Bioservices Closes $65M Series B - Pharma Trend","og_description":"Funding enables August Bio to add capacity for large batch sterile pharmaceutical manufacturing NASHVILLE–(BUSINESS WIRE)–August Bioservices, LLC (\u201cAugust Bio\u201d), a pharmaceutical contract development and manufacturing organization (CDMO) providing drug discovery, development and pharmaceutical manufacturing services, today announced that it secured $65 million in Series B funding led by Oak HC\/FT, who led the Series A ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-01T13:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221201005209\/en\/1651798\/21\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"August Bioservices Closes $65M Series B","datePublished":"2022-12-01T13:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/"},"wordCount":477,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221201005209\/en\/1651798\/21\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/","url":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/","name":"August Bioservices Closes $65M Series B - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221201005209\/en\/1651798\/21\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg","datePublished":"2022-12-01T13:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221201005209\/en\/1651798\/21\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221201005209\/en\/1651798\/21\/AUG_BIO_LOGO_final_TM_FINAL_NEW.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/august-bioservices-closes-65m-series-b\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"August Bioservices Closes $65M Series B"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51450"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51450\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}